AAKAAR AAKAAR Q2 FY26 results (Jul–Sep 2025) and concall
Aakaar Medical Technologies reported a challenging H1 FY26 with sales declining 8.5% YoY to INR 25.3 crores and a negative PAT of INR 0.78 crores, attributed to seasonality, one-time costs, and a strategic shift towards stricter credit controls. Despite this, the company successfully completed its IPO, expanded its own brand portfolio to 38% of turnover, and launched new USFDA-approved products and divisions. Management is focused on improving cash flow by reducing receivable days to below 100 and aims for a healthy rebound in H2 FY26 with a 25-30% CAGR.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q4 FY25 | Q2 FY26 |
|---|---|---|
| Revenue | 34 | 25 |
| EBITDA | 8 | 0 |
| Net profit | 6 | -1 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
